Last reviewed · How we verify
conventional treatment for schizophrenia
At a glance
| Generic name | conventional treatment for schizophrenia |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- rTMS for Depressive, Positive and Negative Symptoms, and Physiological Indices of Schizophrenia Patients (NA)
- High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone (PHASE4)
- Personalized Metacognitive Training for Psychosis: A Randomized Controlled Trial (NA)
- The Effect of Virtual Reality on Cognitive Skills in Schizophrenia (NA)
- Therapeutic Improvement in People With Schizophrenia Undergoing tACS/CBTp (Transcranial Alternating Current Stimulation Applied Pre-cognitive Behavioral Therapy for Psychosis) Associated to Usual Medication Regimen (NA)
- Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and (NA)
- The Sub-Sero Study (PHASE2)
- The Personalized Psychological Treatment for Psychosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- conventional treatment for schizophrenia CI brief — competitive landscape report
- conventional treatment for schizophrenia updates RSS · CI watch RSS
- AstraZeneca portfolio CI